32 ( 58 % ) of 55 patients in the rituximab group and 37 ( 69 % ) of 54 patients in the placebo group had treatment failure within 78 weeks ( Kaplan-Meier cumulative incidence 46 % for rituximab vs 52 % for placebo ( hazard ratio [ HR ] 089 , 95 % CI 055-145 ; p = 065 ) .